This phase II trial studies community hospital identification with magnetic resonance imaging (MRI) and echocardiography in detecting chemotherapy-related cardiotoxicity in patients with stage I-III breast cancer or lymphoma. Diagnostic procedures, such as MRI and echocardiography, may help find and diagnose chemotherapy-related toxicity in patients. Different ways of measuring heart health will be explored to determine if there are easier and faster ways to measure how chemotherapy may negatively impact the function and size of the heart when being treated for breast cancer or lymphoma at a community hospital.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02566109.
PRIMARY OBJECTIVES:
I. To determine if baseline to 2-month measures of left ventricular (LV) volumes, T1/T2 times, and/or aortic pulse wave velocity (all acquired within 10 minutes) can predict baseline to 6-month post chemotherapy deteriorations in left ventricular ejection fraction (LVEF), as measured by a typical 45-min magnetic resonance imaging (MRI).
II. To compare the Albus 10-min MRI metrics with both echocardiography (ECHO) (including pulse wave velocity [PWV]) and cardiac serum biomarkers (TnI) for predicting baseline to 6 month deteriorations in LVEF.
III. To use exploratory algorithmic modeling to obtain optimal strategies for determining the combination of metrics (10-min MR, ECHO, serum biomarkers) at 2-months that predict the 6-month post chemotherapy deteriorations in cardiovascular (CV) function.
OUTLINE:
Patients scheduled for routine chemotherapy undergo a 10-minute fast MRI, a conventional 45-minute MRI, and a two dimensional (2D) and three dimensional (3D) echocardiogram prior to start of treatment.
Trial PhaseNo phase specified
Trial Typeprevention
Lead OrganizationWake Forest NCORP Research Base
Principal InvestigatorWilliam Gregory Hundley
